Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of hematologic tumor prognosis related gene

A blood tumor, gene technology, applied in the field of biomedicine, can solve problems such as unsatisfactory long-term efficacy

Active Publication Date: 2021-09-10
蒙国宇
View PDF4 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0003] VDCLP is currently a commonly used combination chemotherapy regimen for the treatment of adult ALL, including vincristine, anthracycline / anthraquinone drugs, glucocorticoids, cyclophosphamide, L-asparaginase or pegaspargase, but the long-term efficacy Unsatisfactory, the long-term survival rate is only 30% to 40%

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of hematologic tumor prognosis related gene
  • Application of hematologic tumor prognosis related gene
  • Application of hematologic tumor prognosis related gene

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0016] 1. Preparation of RNA-Seq samples

[0017] (1) Construction of the carrier

[0018] Acquisition of target gene fragments: DUX4 / IGH gene templates are all from Shanghai Institute of Hematology. These template gene fragments are all cDNA sequences obtained from B-ALL patient samples, and then constructed into corresponding vectors through restriction enzyme sites (Sequencing is correct); Design specific primers according to the above target fragment sequence according to the experimental purpose and requirements for vector transformation, gene amplification and mutation construction. The specific process is:

[0019] a. After analyzing and determining the target sequence, design specific primers (as shown in Table 1) according to the experimental requirements, such as introducing restriction enzyme sites into the target sequence (note whether the selected enzyme exists in the target sequence or the target fragment) Cutting site), specific tags and mutations, etc., follo...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses application of a hematologic tumor prognosis related gene. The invention provides application of a PTPRM gene, an SMAD1 gene, a CCNJ gene and / or a TMPRSS15 gene in preparation of a product for auxiliary diagnosis and prognosis evaluation of hematologic tumors. The high expression of the gene is directly associated with good prognosis, the prognosis change condition of a patient can be qualitatively evaluated by detecting the expression quantity of the gene, and guiding significance is provided for later clinical intervention.

Description

technical field [0001] The invention belongs to the technical field of biomedicine, and in particular relates to the application of genes related to prognosis of hematological tumors. Background technique [0002] Acute Lymphoblastic Leukemia (ALL) is a progressive hematological malignancy caused by the unlimited proliferation of lymphoblastoid cells in hematopoietic and lymphoid tissues, especially bone marrow, spleen and lymph nodes. ALL is the most common type of leukemia in children, and ALL derived from B-lineage leukemia cells (B-ALL) accounts for 80%. Although available treatments cure more than 80% of children, relapse of ALL remains a leading cause of death in children. The incidence of adult ALL patients is lower than that of children, accounting for 15% to 25% of acute leukemia. However, adult ALL patients have diverse biological characteristics, large clinical heterogeneity, and poor treatment outcomes. Genetic variants associated with good outcomes declined w...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C12Q1/6886
CPCC12Q1/6886C12Q2600/118C12Q2600/158
Inventor 蒙国宇张浩程诺张士彦马晓丹李智慧
Owner 蒙国宇
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com